ProQR is developing a novel investigational drug called QR-421a to treat RP in patients that have USH2 due to a mutation in a specific part of the USH2A gene, called exon 13.
Read One week ago, on July 13th 2019, At Marriot Downtown Philadelphia, was held the 11th Usher Syndrome Conference organized by Usher Syndrome Coalition.
Read Over the last couple of years the Usher Syndrome Society has been collecting portraits and stories of people of all ages living with Usher syndrome.
Read Original text here
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP).
Read We are pleased to share with you the video, transcripts, slides and summaries of the 2018 International Symposium on Usher Syndrome in Mainz, Germany.
Read Last week the International Symposium on Usher Syndrome was held in Mainz. It was a 3-day event, we only attended the patient’s symposium as I was afraid that the 2 scientific days would be too complicated to follow anyway (and I would be braindead before the patient program even started…).
Read During the summer of 2017 Stefano Scagliarini contacted NoisyVision to request assistance for his thesis at Politecnico di Milano. We immediately answered, convinced that an external and artistic point of view on Usher syndrome would help to the awareness of the condition.
Read At the moment the reportage of the 3YellowTheWorld Tour is only available in Italian. Many images and information are on the Facebook page of Noisyvision
Read Visions of Everest
by Dario Sorgato
It is bitterly cold at 5am in Dingboche. I did not sleep for even one minute all night.
Read